Michael Moore Sells 65,000 Shares of Viemed Healthcare (NASDAQ:VMD) Stock

Viemed Healthcare, Inc. (NASDAQ:VMD) President Michael Moore sold 65,000 shares of the business’s stock in a transaction on Friday, March 20th. The shares were sold at an average price of $8.77, for a total transaction of $570,050.00. Following the sale, the president directly owned 1,585,812 shares of the company’s stock, valued at approximately $13,907,571.24. The trade was a 3.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Michael Moore also recently made the following trade(s):

• On Thursday, March 19th, Michael Moore sold 40,232 shares of Viemed Healthcare stock. The stock was sold at an average price of $9.21, for a total value of $370,536.72.
• On Wednesday, March 18th, Michael Moore sold 31,570 shares of Viemed Healthcare stock. The stock was sold at an average price of $9.42, for a total value of $297,389.40.

Viemed Healthcare Stock Performance

NASDAQ:VMD traded down $0.51 during mid-day trading on Friday, hitting $8.71. 703,686 shares of the company traded hands, compared to its average volume of 245,033. The stock’s fifty day moving average price is $8.30 and its 200-day moving average price is $7.37. Viemed Healthcare, Inc. has a one year low of $5.93 and a one year high of $10.06. The company has a quick ratio of 1.06, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. The firm has a market cap of $336.21 million, a price-to-earnings ratio of 23.54 and a beta of 1.23.

Viemed Healthcare (NASDAQ:VMD) last posted its quarterly earnings data on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. Viemed Healthcare had a return on equity of 10.72% and a net margin of 5.53%.The firm had revenue of $76.18 million for the quarter, compared to the consensus estimate of $77.70 million.

Wall Street Analysts Forecast Growth

VMD has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Viemed Healthcare to a “hold” rating in a research report on Thursday, January 8th. Wall Street Zen upgraded shares of Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research note on Saturday, February 14th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Viemed Healthcare in a report on Monday, December 29th. Two investment analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VMD. State of Alaska Department of Revenue bought a new stake in shares of Viemed Healthcare during the fourth quarter valued at approximately $25,000. Kemnay Advisory Services Inc. bought a new position in shares of Viemed Healthcare during the fourth quarter worth $46,000. Quarry LP purchased a new position in Viemed Healthcare during the third quarter valued at $48,000. AQR Capital Management LLC purchased a new position in Viemed Healthcare during the first quarter valued at $90,000. Finally, SG Americas Securities LLC bought a new stake in Viemed Healthcare in the 4th quarter valued at $101,000. 74.24% of the stock is currently owned by institutional investors.

Viemed Healthcare Company Profile

Viemed Healthcare, Inc (NASDAQ: VMD) is a provider of home-based respiratory therapy services, specializing in the management of patients requiring long-term mechanical ventilation and pulmonary support. The company’s offerings encompass invasive and noninvasive ventilation, airway clearance therapies, cough assist devices, and supplemental oxygen. Viemed combines durable medical equipment with clinical care, delivering tailored respiratory treatment plans that are overseen by licensed respiratory therapists and registered nurses.

Founded in the early 2010s and headquartered in Birmingham, Alabama, Viemed has grown its footprint to serve patients across multiple states in the United States.